R&D Spending Showdown: Takeda Pharmaceutical Company Limited vs Viking Therapeutics, Inc.

Takeda vs Viking: A Decade of R&D Investment

__timestampTakeda Pharmaceutical Company LimitedViking Therapeutics, Inc.
Wednesday, January 1, 201438209600000022223073
Thursday, January 1, 20153459270000006966842
Friday, January 1, 20163123030000009000499
Sunday, January 1, 201732544100000013741186
Monday, January 1, 201836829800000019040000
Tuesday, January 1, 201949238100000023559000
Wednesday, January 1, 202045583300000031931000
Friday, January 1, 202152608700000044981000
Saturday, January 1, 202263332500000054234000
Sunday, January 1, 202372992400000063806000
Monday, January 1, 2024729924000000
Loading chart...

Unlocking the unknown

R&D Spending: A Tale of Two Companies

In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of innovation and future growth. Takeda Pharmaceutical Company Limited, a global leader, and Viking Therapeutics, Inc., a rising star, present a fascinating contrast in their R&D investments over the past decade.

Takeda's Dominance

From 2014 to 2023, Takeda's R&D expenses have surged by approximately 91%, reflecting its commitment to innovation. In 2023, Takeda's R&D spending reached a staggering 730 billion yen, underscoring its position as a powerhouse in the pharmaceutical industry.

Viking's Steady Growth

Viking Therapeutics, though smaller, has shown impressive growth. From 2014 to 2023, its R&D expenses increased by nearly 187%, highlighting its aggressive pursuit of new therapies. However, Viking's spending remains a fraction of Takeda's, emphasizing the scale difference between the two.

This data offers a glimpse into the strategic priorities of these companies, with Takeda focusing on maintaining its leadership and Viking striving to carve out its niche.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025